Navigation Links
Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
Date:2/24/2010

OMAHA, Neb., Feb. 24 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder.  Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010.  Financial terms of the agreement were not disclosed.

"We are pleased to have the opportunity to develop and offer a genetic test to clinicians and parents that will assist in the evaluation of children who are thought to be at high risk of being autistic," stated '/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
2. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
3. Transgenomic, Inc. Reports Third Quarter 2009 Results
4. Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease
5. Transgenomic, Inc. Reports Second Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
7. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
8. Transgenomic, Inc. Announces Appointment of New Board Members
9. Transgenomic, Inc. Reports First Quarter 2009 Results
10. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
11. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... SAN FRANCISCO, Calif., Sept. 7 Monogram,Biosciences, Inc. (Nasdaq: ... CEO,and Chairman, is scheduled to present a corporate overview ... September 17,2007 at 1:30 p.m. Eastern Time (10:30 a.m. ... California. To access the live audio broadcast or ...
... Thursday, October,18, 2007, Wyeth (NYSE: WYE ) will ... will hold a one-hour conference call with,research analysts at ... and others may listen to the call live or ... be accessed by visiting our website,at http://www.wyeth.com ...
... Identify microRNA Biomarkers for Overall Survival and Risk ... of Melanoma Metastasizing to Distant Sites, REHOVOT, ... ROSG ), a global leader in the field of,microRNA ... with,NYU Medical Center to leverage the significant potential of microRNA,profiles ...
Cached Biology Technology:Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 3NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 4NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 5
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... reason about the natural world? How do they understand ... decades, the consensus was that as young children begin ... stance, favoring humans over non-human animals when it comes ... Northwestern University researchers have taken another look at the ...
... Research Fellow at the Department of Medicine, University of Auckland ... and Outcomes Research at Amaris, UK, have been announced as ... The award, an honorarium of 2,000 Euros each, was ... (first authors under the age of 40) that were submitted ...
... Hinxton, 10 May 2010 The European Nucleotide Archive ... to become Europe,s primary access point to globally comprehensive ... available from the European Bioinformatics Institute (EMBL-EBI), a part ... DNA sequencing has led to previously unimaginable amounts of ...
Cached Biology News:Animals talk, sing and act like humans? 2Enabling easy access to DNA sequence information 2
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
Biology Products: